Key Takeaways

• Long-term use of Depo-Provera (medroxyprogesterone acetate), Depo-SubQ Provera 104, or a Pfizer-authorized generic has been linked to the development of intracranial meningioma — a tumor of the membranes surrounding the brain.
• In December 2025, the FDA added a new warning to the Depo-Provera label expressly identifying meningioma risk after long-term use.
• All federal Depo-Provera lawsuits are consolidated in MDL No. 3140 in the U.S. District Court for the Northern District of Florida before Judge M. Casey Rodgers, with the first bellwether trial expected to begin in December 2026.
• Our firm files qualifying Depo-Provera cases directly into MDL 3140 under Pretrial Order No. 10. We accept qualifying cases nationwide.
• Free, confidential case review. No fee unless we recover compensation for you.

What Is Depo-Provera?

Depo-Provera is a long-acting injectable contraceptive manufactured by Pfizer. The active ingredient, medroxyprogesterone acetate, is administered every three months and is also marketed under the names Depo-SubQ Provera 104 and as a Pfizer-authorized generic. Depo-Provera has been on the U.S. market since 1992 and has been used by tens of millions of women, often for many years at a time.

The Link Between Depo-Provera and Brain Tumors

Meningiomas are tumors that develop from the meninges, the protective membranes surrounding the brain and spinal cord. While most meningiomas are non-cancerous, they can grow large enough to cause severe headaches, vision loss, seizures, hearing loss, cognitive impairment, and other neurological complications — often requiring craniotomy (open brain surgery), Gamma Knife or stereotactic radiation, or long-term monitoring with serial MRIs.

A 2024 peer-reviewed study published in The BMJ found that prolonged use of medroxyprogesterone acetate was associated with a significantly elevated risk of intracranial meningioma. In December 2025, the U.S. Food and Drug Administration added a new warning to the Depo-Provera label expressly identifying meningioma risk after long-term use — years after similar warnings had been added to the European and Canadian labels.

Plaintiffs in the Depo-Provera litigation allege that Pfizer knew or should have known of the meningioma risk and failed to adequately warn American patients and prescribers.

Who May Qualify

Core Eligibility Criteria

You may qualify for a Depo-Provera meningioma claim if you meet the following criteria:

• Product use. You received Depo-Provera, Depo-SubQ Provera 104, or a Pfizer-authorized generic medroxyprogesterone acetate injection. Cases involving non-authorized third-party generics are evaluated separately.
• Duration of use. You received at least four injections, generally reflecting one year or more of cumulative use.
• Diagnosis. You were diagnosed with an intracranial meningioma confirmed by MRI or CT imaging. Spinal meningioma cases are reviewed on a case-by-case basis.
• Diagnosis timing. Your meningioma was diagnosed within approximately ten years of your last Depo injection.
• Statute of limitations. Your claim is filed within the applicable statute of limitations for your state — typically two or three years from the date you knew or reasonably should have known of the link between Depo-Provera and your tumor.

Cases That Are Generally Stronger

The most heavily documented and highest-value cases generally involve one or more of the following:

• Craniotomy or surgical resection of the meningioma
• Gamma Knife or other stereotactic radiation
• Persistent neurological deficits — vision loss, hearing loss, seizures, cognitive impairment, or motor weakness
• Younger age at diagnosis
• Multiple meningiomas or tumor recurrence after treatment

“Watch and wait” cases — where a small, asymptomatic meningioma is being monitored without treatment — may still qualify. These cases tend to settle for less than surgical or radiation cases under typical mass-tort settlement grids, but they remain compensable.

Cases We Are Not Generally Accepting

To set realistic expectations up front, we are generally not accepting cases where:

• The brain tumor is something other than a meningioma (for example, glioma, glioblastoma, pituitary adenoma, schwannoma, or acoustic neuroma)
• The meningioma was diagnosed before any Depo-Provera use
• The patient has fewer than four documented Depo injections
• The patient has neurofibromatosis type 2 (NF2) or another hereditary meningioma syndrome (these are reviewed individually but causation can be more difficult)
• The applicable statute of limitations has clearly expired with no available discovery-rule argument

What to Bring to Your Consultation

We obtain medical and pharmacy records on your behalf at no cost as part of our case evaluation. To accelerate the process, it helps if you can gather or identify the following before our call:

• Pharmacy records or prescription history for Depo-Provera going back at least 5–10 years
• Names and locations of any clinics, OB/GYNs, or family doctors who administered the injections
• MRI or CT imaging and the radiologist’s report confirming the meningioma
• The neurosurgery operative report, if you had a craniotomy or resection
• Radiation oncology records, if you had Gamma Knife or other radiation
• A list of treating physicians and any ongoing follow-up appointments
• The approximate date you first connected your Depo-Provera use to your tumor (relevant to the statute-of-limitations analysis)

Compensation Available

Depo-Provera plaintiffs may be entitled to recover both economic and non-economic damages, including:

• Past and future medical expenses — brain surgery, radiation therapy, hospitalization, rehabilitation, prescription medications, and long-term MRI monitoring
• Lost wages and lost earning capacity
• Pain and suffering
• Loss of enjoyment of life
• Permanent neurological injury — vision loss, seizures, hearing loss, cognitive impairment
• In appropriate cases, punitive damages

Settlement values in mass-tort pharmaceutical cases typically follow a settlement-grid structure that pays more for surgically-treated tumors, younger plaintiffs, and plaintiffs with permanent deficits. Each plaintiff retains her own claim and her own recovery — these are individual cases, not a class action.

Where the Litigation Stands (2026 Update)

The Depo-Provera litigation is moving quickly. Key developments and upcoming dates:

• February 7, 2025: The Judicial Panel on Multidistrict Litigation centralized all federal Depo-Provera cases into MDL No. 3140 in the Northern District of Florida before Judge M. Casey Rodgers (the presiding judge in the 3M Combat Arms Earplug MDL).
• March 13, 2025: Judge Rodgers entered Pretrial Order No. 10, authorizing direct filing into the MDL without local counsel.
• December 2025: The FDA added a new meningioma warning to the Depo-Provera label.
• June 24–26, 2026: General-causation Daubert hearings, where the court will decide whether the science linking Depo-Provera to meningioma is admissible at trial.
• December 2026: The first bellwether trial is expected to begin.
• As of mid-2026, more than 3,500 cases have been consolidated in MDL 3140 and the docket is growing rapidly.

How Depo-Provera Cases Work

Depo-Provera lawsuits are mass-tort claims, not a class action. Each plaintiff keeps her own case and her own recovery. Cases are consolidated in MDL 3140 for the efficiency of shared discovery, expert witness practice, and pretrial motions. Bellwether trials test individual verdicts and drive global settlement negotiations.

Our firm files qualifying cases directly into MDL 3140 in the Northern District of Florida under Pretrial Order No. 10. After the MDL pretrial phase is complete, untried cases are remanded back to the federal district where each plaintiff lives for trial.

Why Choose Our Firm

Siddons Law Firm, PLLC handles complex pharmaceutical and medical-device mass-tort cases for women across the United States. Our firm:

• Files qualifying Depo-Provera cases directly into MDL No. 3140 under Pretrial Order No. 10
• Is experienced in federal multidistrict litigation, including active practice in the GLP-1 receptor agonist (Ozempic / Mounjaro / Wegovy) MDL in the Eastern District of Pennsylvania
• Operates on a pure contingency-fee basis — no money up front, no fee unless we recover compensation for you
• Obtains your medical and pharmacy records at no cost as part of the case evaluation
• Accepts referrals and trial team arrangements from out-of-state attorneys

Geographic Reach

Although our firm is headquartered in Pennsylvania, we accept Depo-Provera meningioma cases nationwide through direct filing into MDL 3140 in the Northern District of Florida. Our attorneys are admitted to federal court in Pennsylvania, New Jersey, New York, and Maryland, and we appear pro hac vice in other federal districts where remand cases are tried.

For Referring Attorneys

If you are an attorney with one or more potential Depo-Provera meningioma cases that you would like to refer or trial team, we welcome the conversation. We work under written referral and trial team agreements that comply with Pennsylvania Rule of Professional Conduct 1.5(e) and analogous rules in other jurisdictions, including written client consent to the fee division. We are equipped to handle MDL pretrial proceedings, plaintiff fact sheets, records collection, and bellwether participation. Contact Michael Siddons directly at (610) 255-7500 or msiddons@siddonslaw.com.

Frequently Asked Questions

How long do I have to file a Depo-Provera claim?

The statute of limitations is typically two years in Pennsylvania and New Jersey, and three years in New York and Maryland. The clock generally starts when you knew or reasonably should have known of the connection between Depo-Provera and your meningioma — not when you first received the injection. The December 2025 FDA label change and the accompanying media coverage may be a triggering event for many women. Because the analysis depends on your individual facts, do not assume your claim has expired without first speaking with an attorney.

I don’t remember exact dates. Can I still file?

Yes. Pharmacy records, medical records, and insurance billing histories typically establish when and how often Depo-Provera was administered. We obtain those records on your behalf at no cost.

What if I received a generic, not brand-name Depo-Provera?

Pfizer-authorized generic medroxyprogesterone acetate cases are generally accepted on the same basis as brand-name Depo-Provera. Cases involving non-authorized third-party generics are evaluated separately, and the legal landscape for those claims continues to develop.

Does my tumor need to have been surgically removed?

No. Women with meningiomas that are being actively monitored, treated with radiation (Gamma Knife or stereotactic), or surgically removed may all qualify. Cases involving surgery or radiation are typically valued higher under settlement-grid structures, but “watch and wait” cases remain compensable.

Do I have to travel to Florida for my case?

No. While Depo-Provera cases are consolidated in MDL 3140 in the Northern District of Florida for pretrial proceedings, the vast majority of MDL work is handled remotely. After the MDL pretrial phase is complete, untried cases are remanded back to the federal district where you live for trial.

Is this a class action?

No. The Depo-Provera litigation is a mass tort, not a class action. Each plaintiff has her own individual case and her own individual recovery. Cases are consolidated in MDL 3140 only for the efficiency of shared discovery and pretrial proceedings.

Free Depo-Provera Case Screening

Start Your Depo-Provera Case Today

If you or a loved one received Depo-Provera and were later diagnosed with a meningioma, contact us for a free, confidential case review. There is no cost to have your case evaluated, and you pay nothing unless we recover compensation for you.

Call (610) 255-7500 or email msiddons@siddonslaw.com. Cases accepted nationwide.